JP2024019727A5 - - Google Patents

Download PDF

Info

Publication number
JP2024019727A5
JP2024019727A5 JP2023223638A JP2023223638A JP2024019727A5 JP 2024019727 A5 JP2024019727 A5 JP 2024019727A5 JP 2023223638 A JP2023223638 A JP 2023223638A JP 2023223638 A JP2023223638 A JP 2023223638A JP 2024019727 A5 JP2024019727 A5 JP 2024019727A5
Authority
JP
Japan
Prior art keywords
sgrna
nme
nucleotides
length
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023223638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024019727A (ja
Filing date
Publication date
Priority claimed from JP2020525971A external-priority patent/JP2021502097A/ja
Application filed filed Critical
Publication of JP2024019727A publication Critical patent/JP2024019727A/ja
Publication of JP2024019727A5 publication Critical patent/JP2024019727A5/ja
Pending legal-status Critical Current

Links

JP2023223638A 2017-11-10 2023-12-28 標的化crispr送達プラットフォーム Pending JP2024019727A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762584310P 2017-11-10 2017-11-10
US62/584,310 2017-11-10
US201762596375P 2017-12-08 2017-12-08
US62/596,375 2017-12-08
US201862667084P 2018-05-04 2018-05-04
US62/667,084 2018-05-04
JP2020525971A JP2021502097A (ja) 2017-11-10 2018-11-09 標的化crispr送達プラットフォーム
PCT/US2018/060126 WO2019094791A2 (en) 2017-11-10 2018-11-09 Targeted crispr delivery platforms

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020525971A Division JP2021502097A (ja) 2017-11-10 2018-11-09 標的化crispr送達プラットフォーム

Publications (2)

Publication Number Publication Date
JP2024019727A JP2024019727A (ja) 2024-02-09
JP2024019727A5 true JP2024019727A5 (https=) 2025-04-17

Family

ID=66438139

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020525971A Withdrawn JP2021502097A (ja) 2017-11-10 2018-11-09 標的化crispr送達プラットフォーム
JP2023223638A Pending JP2024019727A (ja) 2017-11-10 2023-12-28 標的化crispr送達プラットフォーム

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020525971A Withdrawn JP2021502097A (ja) 2017-11-10 2018-11-09 標的化crispr送達プラットフォーム

Country Status (13)

Country Link
US (3) US20220389447A9 (https=)
EP (1) EP3707254A4 (https=)
JP (2) JP2021502097A (https=)
KR (2) KR102922730B1 (https=)
CN (1) CN111868240A (https=)
AU (2) AU2018364993B2 (https=)
BR (1) BR112020009268A2 (https=)
CA (1) CA3082370A1 (https=)
CO (1) CO2020007046A2 (https=)
IL (2) IL317505A (https=)
MX (1) MX2020004777A (https=)
SG (1) SG11202005103RA (https=)
WO (1) WO2019094791A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3868887A4 (en) * 2018-09-25 2022-12-07 Microbial Chemistry Research Foundation NOVEL VIRAL VECTOR AND METHODS OF PRODUCTION AND USE THEREOF
CN113661392B (zh) 2019-02-05 2025-05-27 卡蒂亚生物公司 有效靶向基因组操纵剂的增强选择
US20220298494A1 (en) * 2019-02-14 2022-09-22 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
CN110257406B (zh) * 2019-06-21 2022-07-22 安徽省农业科学院水稻研究所 密码子植物化改造的Plant Nme2Cas9基因及其应用
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
WO2021122944A1 (en) 2019-12-18 2021-06-24 Alia Therapeutics Srl Compositions and methods for treating retinitis pigmentosa
CN113652411B (zh) * 2021-07-30 2025-01-10 复旦大学 Cas9蛋白、含有Cas9蛋白的基因编辑系统及应用
CA3225082A1 (en) 2021-08-27 2023-03-02 Brian C. Thomas Enzymes with ruvc domains
US20230183687A1 (en) * 2021-10-13 2023-06-15 University Of Massachusetts Modified guide rnas for neisseria meningitidis cas9
WO2023081687A1 (en) * 2021-11-03 2023-05-11 Intellia Therapeutics, Inc. Modified guide rnas for gene editing
EP4426822A2 (en) 2021-11-03 2024-09-11 Intellia Therapeutics, Inc. Polynucleotides, compositions, and methods for genome editing
WO2023240076A1 (en) 2022-06-07 2023-12-14 Scribe Therapeutics Inc. Compositions and methods for the targeting of pcsk9
WO2024137766A2 (en) 2022-12-21 2024-06-27 Intellia Therapeutics, Inc. Compositions and methods for proprotein convertase subtilisin kexin 9 (pcsk9) editing
WO2024186890A1 (en) 2023-03-06 2024-09-12 Intellia Therapeutics, Inc. Compositions and methods for hepatitis b virus (hbv) genome editing
TW202515994A (zh) 2023-08-14 2025-04-16 美商英特利亞醫療公司 用於對cd70進行基因修飾之組合物及方法
WO2025038637A1 (en) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
TW202521564A (zh) 2023-08-14 2025-06-01 美商英特利亞醫療公司 用於基於細胞之療法的cd70 car-t組合物及方法
AU2024324870A1 (en) 2023-08-14 2026-02-12 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
WO2025255308A1 (en) 2024-06-07 2025-12-11 Intellia Therapeutics, Inc. Cd8 co-receptor chimeric polypeptides in tcr cell therapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3241902B1 (en) * 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
MX2015017312A (es) * 2013-06-17 2017-04-10 Broad Inst Inc Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
WO2015006294A2 (en) * 2013-07-10 2015-01-15 President And Fellows Of Harvard College Orthogonal cas9 proteins for rna-guided gene regulation and editing
EP3760719A1 (en) * 2013-11-18 2021-01-06 CRISPR Therapeutics AG Crispr-cas system materials and methods
CN106103699B (zh) * 2013-11-28 2019-11-26 地平线探索有限公司 体细胞单倍体人类细胞系
JP6793547B2 (ja) * 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
EP3080259B1 (en) 2013-12-12 2023-02-01 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
WO2016049258A2 (en) * 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
US10190106B2 (en) * 2014-12-22 2019-01-29 Univesity Of Massachusetts Cas9-DNA targeting unit chimeras
US20160346359A1 (en) * 2015-05-01 2016-12-01 Spark Therapeutics, Inc. Adeno-associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease
WO2018085414A1 (en) * 2016-11-02 2018-05-11 President And Fellows Of Harvard College Engineered guide rna sequences for in situ detection and sequencing
BR112019028146A2 (pt) * 2017-07-31 2020-07-07 Sigma-Aldrich Co. Llc rna guia sintético para sistemas ativadores de crispr/cas

Similar Documents

Publication Publication Date Title
JP2024019727A5 (https=)
Parambi et al. Gene therapy approach with an emphasis on growth factors: theoretical and clinical outcomes in neurodegenerative diseases
AU2019258678B2 (en) Lipid-based formulations for the delivery of RNA
Rettig et al. Progress toward in vivo use of siRNAs-II
Sago et al. Cell subtypes within the liver microenvironment differentially interact with lipid nanoparticles
BR112017012482B1 (pt) Composição, usos de uma composição, e, métodos para liberar um ácido nucleico a uma célula ou tecido alvo e para a produção da composição
WO2024087423A1 (zh) 递送至体内后在肝脏少表达的mRNA药物及其制备方法
WO2023124740A1 (zh) 肌肉高亲和性的新型腺相关病毒衣壳蛋白及其应用
CN120019152A (zh) 用于表达蛋白质的人工多核苷酸
Leclerc et al. Next-generation biological vector platforms for in vivo delivery of genome editing agents
JP2024511808A (ja) ウイルスベクターに基づくrna送達システム及びその使用
JP2022523806A (ja) 閉端dna(cedna)および免疫調節化合物
Mathew et al. Heat-shrinking DNA nanoparticles for in vivo gene delivery
KR20220007601A (ko) 치료제 투여를 위한 조성물 및 방법
KR102685034B1 (ko) 금속 나노 입자-핵산 결합체를 기반으로 하는 유전자 운반체
WO2024236361A1 (en) Compositions and methods for delivery of nucleic acids to cells
CN119998457A (zh) 基于金属纳米颗粒-核酸缀合物的基因载体
EP3836903B1 (en) Lipid-based formulations containing salts for the delivery of rna
Chand et al. Advances in Gene Therapy for Neurologic Disorders: An Overview
Singh et al. The Junction of Biomaterials and Gene Therapy–Current Strategies and Future Directions
CN118634243B (zh) Mir2911在制备抗登革病毒denv的药物中的应用
US20250376664A1 (en) Virus-Ribonucleoprotein Conjugates
RU2815001C2 (ru) Составы на основе липидов для доставки рнк
NZ805346A (en) Targeted crispr delivery platforms
Grol et al. Prospects of gene therapy for skeletal diseases